BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34698568)

  • 21. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
    Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
    J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer.
    Komatsu H; Mizuguchi S; Izumi N; Chung K; Hanada S; Inoue H; Suehiro S; Nishiyama N
    World J Surg Oncol; 2013 Dec; 11():309. PubMed ID: 24313932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.
    Matsunaga T; Suzuki K; Takamochi K; Oh S
    Eur J Cardiothorac Surg; 2014 Jul; 46(1):86-91. PubMed ID: 24321998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
    He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
    Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
    Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
    J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects.
    Zhang R; Chen C; Dong X; Shen S; Lai L; He J; You D; Lin L; Zhu Y; Huang H; Chen J; Wei L; Chen X; Li Y; Guo Y; Duan W; Liu L; Su L; Shafer A; Fleischer T; Moksnes Bjaanæs M; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
    Chest; 2020 Aug; 158(2):808-819. PubMed ID: 32113923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients 
Treated with Surgery].
    Yang H; Dai L; Li P; Shen L; Yan W; Fan M; Chen K
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):505-11. PubMed ID: 26302348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
    de Jong EEC; van Elmpt W; Rizzo S; Colarieti A; Spitaleri G; Leijenaar RTH; Jochems A; Hendriks LEL; Troost EGC; Reymen B; Dingemans AC; Lambin P
    Lung Cancer; 2018 Oct; 124():6-11. PubMed ID: 30268481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
    Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
    J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2?
    Rea F; Marulli G; Callegaro D; Zuin A; Gobbi T; Loy M; Sartori F
    Lung Cancer; 2004 Aug; 45(2):215-20. PubMed ID: 15246193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
    Lu Y; Wang L; Liu P; Yang P; You M
    PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China.
    Wang RQ; Long XR; Ge CL; Zhang MY; Huang L; Zhou NN; Hu Y; Li RL; Li Z; Chen DN; Zhang LJ; Wen ZS; Mai SJ; Wang HY
    J Transl Med; 2020 Aug; 18(1):320. PubMed ID: 32819367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.
    Wang CL; Li Y; Yue DS; Zhang LM; Zhang ZF; Sun BS
    World J Surg; 2012 Feb; 36(2):455-62. PubMed ID: 22187129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer-aided diagnosis of distal metastasis in non-small cell lung cancer by low-dose CT based radiomics and deep learning signatures.
    Song X; Duan X; He X; Wang Y; Li K; Deng B; Chen X; Wang Y; Li M; Shan H
    Radiol Med; 2024 Feb; 129(2):239-251. PubMed ID: 38214839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study.
    Zhong Y; Cai C; Chen T; Gui H; Chen C; Deng J; Yang M; Yu B; Song Y; Wang T; Chen Y; Shi H; Xie D; Chen C; She Y
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):521-534. PubMed ID: 37725128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.